Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Matthew S. Davids, Ugochinyere Emeribe, Priyanka Gaitonde, Ling Cai
Institutions: Dana-Farber Cancer Institute, AstraZeneca (United States)
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3212978684